ClinicalTrials.gg

Program

VERVE-102

A development code.

Its studies are mostly in Atherosclerosis · Hyperlipoproteinemia Type II, led by Eli Lilly.

Furthest: phase 2, since Sep 18, 20262 company-led studies, 2 open or runningNext primary completion: Aug 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly22 open or runningphase 2since Sep 18, 2026Dec 1, 2023Aug 2028phase 2 · NCT07839936

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2023First study: phase 1 study in Hyperlipoproteinemia Type IIFirst studyNCT06164730 · 85 planned · United States, Australia, Canada and more
  2. Sep 18, 2026Phase 2 study in AtherosclerosisPhase 2 reachedNCT07839936 · 175 planned · United States

Ahead

  1. Aug 2028Primary completion: phase 2 study in AtherosclerosisNCT07839936

TargetBeta

“VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C.”study text, read by Claude · the study

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07839936Atherosclerosis · United States2RecruitingAug 2028175
NCT06164730Hyperlipoproteinemia Type II · United States, Australia, Canada and more1RecruitingOct 202685

How it is read

Names in the registry

  • “VERVE-102”, 2 entries

Codes read as this program: VERVE102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.